Gene-targeting therapy for ANXA2, a biological target, provides a new therapeutic approach to alleviate dysmenorrhea in AM patients and to meet the conservative and fertility requirements of some patients after the open second-child policy. Here, ANXA2 is linked to acute myeloblastic leukemia with maturation.